Extended indication Extension of indication to include treatment of metastatic colorectal cancer in adult patients where it is not possible to initiate or continue treatm
Therapeutic value No judgement
Registration phase Registration application pending

Product

Active substance Tegafur / gimeracil / oteraci
Domain Oncology and Hematology
Reason of inclusion Indication extension IND
Main indication Colon cancer
Extended indication Extension of indication to include treatment of metastatic colorectal cancer in adult patients where it is not possible to initiate or continue treatment with another fluoropyrimidine.
Proprietary name Teysuno
Manufacturer Nordic Pharma
Mechanism of action Other, see general comments
Route of administration Unknown
Therapeutical formulation Unknown
Budgetting framework Intermural (MSZ)
Additional remarks DNA synthese remmer.

Registration

Registration route Centralised (EMA)
Type of trajectory Unknown
Particularity Unknown
ATMP Unknown
Submission date November 2020
Expected Registration September 2021
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No judgement

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

References medicijnkosten.nl
Additional remarks Capsule 15MG/4,35MG/11,8MG is € 3,40 per stuk en een capsule van 20MG/5,8MG/15,8MG is € 5,18 per stuk.

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information